Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Carol Stiff

- PMLiVE

Oxford University, Prenetics to advance COVID-19 rapid testing for other infectious diseases

Rapid testing technology at the core of the collaboration is used in Oxford University's COVID-19 test

- PMLiVE

EMA finds overall benefit-risk ‘remains positive’ for J&J COVID-19 vaccine

Safety committee finds possible link to ‘very rare cases’ of unusual blood blots with low blood platelets

- PMLiVE

WHO director-general says pandemic can be brought under control within months

World has tools to curb pandemic if applied ‘consistently and equitably’

- PMLiVE

NICE sets out plans for ‘ambitious’ five-year strategy

NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments

- PMLiVE

UK-based challenge study to re-expose healthy adults to COVID-19

Study will enrol participants aged 18-30 who have previously been infected with COVID-19

- PMLiVE

Moderna COVID-19 vaccine shortfall could affect UK supply

But deliveries to the EU and Switzerland are not affected by the supply issues

- PMLiVE

Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

Decision prompted by the ‘evolving variant landscape’ in the US

- PMLiVE

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

Company is aiming to receive European approval in June

When Wireless Technology Meets Drug Delivery

Robert Niichel, Founder/CEO of SmartTab, explores the concept of personalized wireless drug delivery, including its advantages, barriers, and current status. We also discuss the future of digital medicine, the Internet...

Impetus Digital

Effective Leadership During & After the COVID-19 Pandemic

Carol Stiff, Head of Canada at Santen, delves into what effective leadership looks like before, during, and after COVID-19; challenges brought on by the pandemic; the importance of developing partnerships...

Impetus Digital

- PMLiVE

Merck & Co halts development of potential COVID-19 drug MK-7110

Pharma company has abandoned drug due to technical, clinical and regulatory uncertainties

- PMLiVE

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links